Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Spero Therapeutics reports progress in drug candidates and financial stability

Spero Therapeutics showcased progress in key drug candidates and financial stability.
Efficient management of expenses and strong cash position support future operations.
Challenges include successful Phase III trials and proof of concept for key treatments.
Opportunities lie in market potential for drug candidates and positive financial outlook.

Spero Therapeutics advances clinical programs and strengthens financial position

Spero Therapeutics demonstrated strong clinical and financial performance in Q1 2023, with a robust pipeline and efficient cost management.
While facing timeline challenges and the need for regulatory milestones, the company's strengths in infectious disease treatments and strategic partnerships present growth opportunities.
By addressing challenges, leveraging strengths, and capitalizing on opportunities, Spero is poised for continued success and potential market leadership in the pharmaceutical sector.

Spero Therapeutics reports Q2 progress with strategic leadership changes

Spero Therapeutics reported Q2 revenues of $2.7 million with a net loss of $11.9 million, holding $77.7 million in cash.
Progress in late-stage clinical programs and management changes signal strategic advancements and leadership continuity.
Challenges include managing R&D investments, competitive market dynamics, and clear execution of growth strategies.
Opportunities lie in revenue growth from milestones, pipeline expansion, differentiation strategies, and strategic partnerships.

Spero Therapeutics reports strong Q3 performance amidst strategic shifts

Spero Therapeutics showcased solid revenue generation and cash reserves in Q3 2023, underpinned by strategic partnerships and pipeline advancements.
While facing challenges such as increased expenses and impairment costs, the company's leadership changes and innovative programs position it for long-term success.
Opportunities lie in upcoming clinical data releases, expansion of product pipelines, and substantial revenue potential from key partnerships, signaling a promising outlook for Spero.

Spero Therapeutics excels in antibiotic development with strong financial backing

Spero Therapeutics demonstrated strong performance in advancing key programs and securing financial support, positioning the company for future growth.
While facing challenges in enrollment and funding, the opportunities in addressing critical infections present a promising outlook for Spero Therapeutics.

Spero Therapeutics reports Q2 revenue growth amidst leadership transition

Spero Therapeutics showcased solid revenue but faced rising R&D costs and leadership changes.
The company's financial stability is supported by cash reserves and expected milestone payments.
Opportunities lie in pipeline advancements, upcoming data releases, and strategic investor communication.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced publication in The New England Journal of Medicine (NEJM) of the results from the Phase 3 ADAPT-PO clinical trial for its investigational oral carbapenem antibiotic, tebipenem pivoxil hydrobromide (tebipenem HBr). The paper, titled “Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection,” is available online at the New England Journal of Medicine (NEJM).

Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q4 2021 Results - Earnings Call Transcript

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -12.50% and 5.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates

Provides update on ongoing FDA review of Tebipenem HBr NDA

Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update

Spero Therapeutics (SPRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Spero Therapeutics (SPRO) This Earnings Season?

CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022, at 4:30 p.m. ET to report its fourth quarter and full-year 2021 financial results and provide an update on its business and pipeline.

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022

SPR206 shown to be well-tolerated; achieved lung exposures consistent with predicted therapeutic levels, when administered three times daily at 100 mg

Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital

New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7 million New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7 million

Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients

The FDA has lifted the clinical hold on Spero Therapeutics Inc's (NASDAQ: SPRO) Phase 2 trial of SPR720 for nontuberculous mycobacterial (NTM) disease. The SPR720 program was placed on a clinical hold by the FDA following a review of data from a non-human primate (NHP) toxicology study in which mortalities with inconclusive causality to treatment were observed.

FDA Lifts Clinical Hold On Spero Therapeutics' Lung Infection Program

Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.

Spero (SPRO) Application for UTI Drug Gets Priority Review

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Spero's investigational oral product candidate being developed for nontuberculous mycobacterial (NTM) disease.

Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720

The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022 The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022

Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q3 2021 Results - Earnings Call Transcript

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 0.00% and 2.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on Wednesday, November 10, 2021, at 4:30 p.m. ET to report its third quarter 2021 financial results and provide an update on its business and pipeline.

Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms. If approved, tebipenem HBr would be the only oral carbapenem antibiotic available for use in cUTI.

Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis

Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero's Board Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero's Board

Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors

Spero Therapeutics Inc (NASDAQ: SPRO) has entered into a revenue interest financing agreement with HealthCare Royalty Partners for up to $125 million.  Spero will use the proceeds to prepare for the anticipated launch of tebipenem HBr and support the continued clinical development of SPR720 and SPR206.

Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners

Investment expected to extend Spero Therapeutics' cash runway into 2H 2023 Investment expected to extend Spero Therapeutics' cash runway into 2H 2023

Spero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® for Up to $125 Million

CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 – October 3, 2021. Presentations will showcase in vitro and in vivo studies of Spero's oral antibiotic investigational candidate tebipenem HBr for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) and highlight additional research on the epidemiology and management of cUTI.

Spero Therapeutics to Present Data at IDWeek 2021

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for virtual one-on-one meetings at the H.C. Wainwright 23rd Annual Global Investment Conference, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, and the 2021 Cantor Virtual Global Healthcare Conference, taking place virtually September 13 – 15th, 2021, September 20 – 23rd, 2021, and September 27 – 30th, 2021, respectively.

Spero Therapeutics to Present at Three Upcoming Investor Conferences

Does Spero Therapeutics, Inc. (SPRO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2021 Results - Earnings Call Transcript

Shares of Spero Therapeutics (NASDAQ:SPRO) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 25.88% over the past year to ($0.63), which beat the estimate of ($0.77).

News for Spero Therapeutics Stock (SPRO)